Cytomed Therapeutics Announced That The Intellectual Property Corporation Of Malaysia Has Granted A Patent For Its Chimeric Antigen Receptor Gamma Delta T Cell Technology, Which Targets Solid And Hematological Tumors
Cytomed Therapeutics Announced That The Intellectual Property Corporation Of Malaysia Has Granted A Patent For Its Chimeric Antigen Receptor Gamma Delta T Cell Technology, Which Targets Solid And Hematological Tumors
Cytomed Therapeutics宣佈，馬來西亞知識產權公司已批准其針對實體腫瘤和血液學腫瘤的嵌合抗原受體伽瑪德爾塔T細胞技術的專利
Cytomed Therapeutics Announced That The Intellectual Property Corporation Of Malaysia Has Granted A Patent For Its Chimeric Antigen Receptor Gamma Delta T Cell Technology, Which Targets Solid And Hematological Tumors
Cytomed Therapeutics宣佈，馬來西亞知識產權公司已批准其針對實體腫瘤和血液學腫瘤的嵌合抗原受體伽瑪德爾塔T細胞技術的專利
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。